{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 58,
  "pageCount": 64,
  "prevPage": 57,
  "nextPage": 59,
  "slideType": "executive_summary",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes multiple citations and diagrams of molecular mechanism and clinical trial results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/58",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-58",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.5,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Clinical trial results for Ulcerative Colitis and Crohn's Disease",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "373e454f-60c4-4aa4-b619-d7395ffb0b30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.1,
        "x": 0.85,
        "y": 0.55
      },
      "kind": "chart",
      "text": "Inflammation score in mouse models",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b89a8371-20c9-4927-9aed-987fad6fd233",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.5,
        "y": 0.45
      },
      "kind": "diagram",
      "text": "Mechanism of action showing GLUT1 inhibition and metabolic consequences",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8a9f64d0-f291-44e3-892c-94cdbaea3d8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.05,
        "y": 0.38
      },
      "kind": "image",
      "text": "iMX-120 molecular structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dd0e713-ce6b-415e-8c60-68bcb0a6e511",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.02,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "iMX-120 is a Tissue-Specific Biologic with Immune Normalization Technology encapsulating anti-inflammatory poly-kinase inhibitors (polyphenols) with proprietary targeting (GLUT1/ confidential targets) selectively silencing disease-causing inflammatory bowel immune cells.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e95fccef-cbc2-4104-95a2-1e06aebb6958",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Adapted from Marzo et al, Lang et al, Alzahrani et al, Macintyre et al, Renaudin et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c97bc50-b1ab-4836-b250-f4917de56cca",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "IMX-120 GLUT1 Biomarker-targeted for Inflammatory Bowel Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92d8a3d9-45f1-4c72-bd9a-a5c8f30680aa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "11f030e4-fa91-43c8-98cb-a9993fe98703",
      "evidence": "The slide is titled 'executive_summary' and features a paragraph/paragraph component, which is a clear indicator of an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 64,
      "from": 37,
      "beatId": "55323ebe-ee93-4119-be72-15ce337e4875",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 37-64 discuss the market opportunity, clinical development plan, and upcoming catalysts",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}